BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AskBio readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies AskBio's drugs run\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07215403-1583@assetmemo.bio
DTSTAMP:20261121T005311Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ametefgene parvec: Phase 2 readout est. (NCT07215403)
DESCRIPTION:Ametefgene parvec\, phase 2\, Parkinson's Disease.\nStudy: Open
 -Label\, Multi-Stage Study to Optimize the Intraputaminal Administration o
 f AB-1005 Using a Prescriptive Infusion Algorithm (PIA)\nEstimated primary
  completion: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ametefgene-parvec#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07215403
URL:https://assetmemo.bio/drug/ametefgene-parvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06285643-1583@assetmemo.bio
DTSTAMP:20261121T005311Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ametefgene parvec: Phase 2 readout est. (NCT06285643)
DESCRIPTION:Ametefgene parvec\, phase 2\, Parkinson's Disease.\nStudy: A St
 udy of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-P
 D)\nEstimated primary completion: 31 August 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ametefgene-parvec#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06285643
URL:https://assetmemo.bio/drug/ametefgene-parvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
